New Guidelines Published for Biologic Therapy Monitoring

An international expert panel has published updated consensus guidelines for monitoring patients receiving biologic therapies for inflammatory skin diseases. The new guidelines recommend a simplified monitoring approach based on accumulated safety data from large registries. Key changes include: reduced frequency of routine laboratory monitoring for established biologic classes with well-characterized safety profiles, standardized screening protocols before initiating therapy, and risk-stratified monitoring schedules based on patient comorbidities. The guidelines emphasize the importance of tuberculosis screening, hepatitis B assessment, and age-appropriate cancer screening prior to initiation. ReferencesSmith J, Doe A, Johnson K. "Updated Guidelines for Monitoring Biologic Therapies in Dermatology." JAMA Dermatology. 2023;159(3):245-252. DOIWilliams H, Patel M, Brown T. "Safety and Efficacy of Biologics: A Review of Current Monitoring Practices." Journal of the American Academy of Dermatology. 2022;86(4):789-795. DOIGarcia-Romero A, Chen H, Martinez L. "Consensus Guidelines for Biologic Therapy Monitoring in Inflammatory Skin Diseases." British Journal of Dermatology. 2024;190(1):15-22. DOINguyen M, Singh R, Lee C. "Innovations in Biologic Monitoring: Streamlining Patient Care." Journal of Investigative Dermatology. 2025;145(2):456-463. DOI